Encorafenib and binimetinib followed by radiotherapy for patients with BRAFV600-mutant melanoma and brain metastases (E-BRAIN/GEM1802 phase II study)

• Published in: Neuro-oncology (Charlottesville, Va.) Vol. 26; no. 11; pp. 2074 - 2083
• Main Authors: Márquez-Rodas, Iván, Álvarez, Ana, Arance, Ana, Valduvieco, Izaskun, Berciano-Guerrero, Miguel-Ángel, Delgado, Raquel, Soria, Ainara, López Campos, Fernándo, Sánchez, Pedro, Luis Romero, Jose, Martin-Liberal, Juan, Lucas, Anna, Díaz-Beveridge, Roberto, Conde-Moreno, Antonio-José, Álamo de la Gala, Maria Del Carmen, García-Castaño, Almudena, José Prada, Pedro, González Cao, María, Puertas, Enrique, Vidal, Joana, Foro, Palmira, Aguado de la Rosa, Carlos, Corona, Juan Antonio, Cerezuela-Fuentes, Pablo, López, Paco, Luna, Pablo, Aymar, Neus, Puértolas, Teresa, Sanagustín, Pilar, Berrocal, Alfonso
• Format: Journal Article
• Language: English
• Published: England Oxford University Press 01.07.2024
• Subjects: Clinical Investigations; Encorafenib and binimetinib; Radiotherapy; Targeted Therapy; Brain metastasis; Melanoma
• ISSN: 1522-8517; 1523-5866; 1523-5866
• DOI: 10.1093/neuonc/noae116

Encorafenib plus binimetinib (EB) is a standard of care treatment for advanced BRAFV600-mutant melanoma. We assessed efficacy and safety of encorafenib plus binimetinib in patients with BRAFV600-mutant melanoma and brain metastasis (BM) and explored if radiotherapy improves the duration of response. E-BRAIN/GEM1802 was a prospective, multicenter, single arm, phase II trial that enrolled patients with melanoma BRAFV600-mutant and BM. Patients received encorafenib 450 mg once daily plus binimetinib 45 mg BID, and those who achieved partial response or stable disease at first tumor assessment were offered radiotherapy. Treatment continued until progression.Primary endpoint was intracranial response rate (icRR) after 2 months of EB, establishing a futility threshold of 60%. The study included 25 patients with no BM symptoms and 23 patients with BM symptoms regardless of using corticosteroids. Among them, 31 patients (64.6%) received sequential radiotherapy. After two months, icRR was 70.8% (95% CI: 55.9-83.1); 10.4% complete response. Median intracranial PFS and OS were 8.5 (95% CI: 6.4-11.8) and 15.9 (95% CI: 10.7-21.4) months, respectively (8.3 months for icPFS and 13.9 months OS for patients receiving RDT). Most common grade 3-4 treatment-related adverse event was alanine aminotransferase (ALT) increased (10.4%). Encorafenib plus binimetinib showed promising clinical benefit in terms of icRR, and tolerable safety profile with low frequency of high grade TRAEs, in patients with BRAFV600-mutant melanoma and BM, including those with symptoms and need for steroids. Sequential radiotherapy is feasible but it does not seem to prolong response.